NISHIYAMA Hiroyuki

Researcher's full information

Articles

• Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper
  Matsumoto Hiroaki; Shiraishi Koji; Azuma Haruhito; Ino...
  INTERNATIONAL JOURNAL OF UROLOGY/27(5)/pp.362-368, 2020-05
  
  PubMed
• Impact of centralization in primary retroperitoneal sarcoma treatment: analysis using hospital-based cancer registry data in Japan
  Kimura Tomokazu; Kawai Koji; Kandori Shuya; Nitta Satosh...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/25(9)/pp.1687-1694, 2020-05
  
  PubMed
• KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC
  Kamat Ashish M.; Shore Neal; Hahn Noah; Alanee Shahee...
  FUTURE ONCOLOGY/16(10)/pp.507-516, 2020-04
  
  PubMed
• Co-morbidity among childhood cancer survivors at "the comprehensive medical checkup for CCS at University of Tsukuba Hospital"
  福島紘子; 鈴木涼子; 八牧愉二; 穂坂 翔; 稲葉正子; 新開統子; 増本幸二; 室井 愛; 鶴淵隆夫; 水本斉志; 櫻井英幸; ...
  日本小児血液・がん学会雑誌(第61回日本小児血液・がん学会)/56(4)/pp.252-252, 2019-10
• A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA)
  Kuebler Hubert Rudolf; Powles Thomas; Meeks Joshua I.; ...
  ONCOLOGY RESEARCH AND TREATMENT/43(1)/pp.82-82, 2020-02
• [Screening of Deep Vein Thrombosis Prior to Surgery Using D-dimer Testing and Venous Ultrasonography of Lower Extremities]
  Joraku Akira; Nitta Satoshi; Tanaka Ken; Ichioka Daishi; ...
  Hinyokika kiyo. Acta urologica Japonica, 2017-06
• Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data
  Tanaka Ken; Kandori Shuya; Nitta Satoshi; Chihara Ichiro...
  International journal of urology : official journal of the Japanese Urological Association, 2020-04
  
  PubMed
• Solitary Bladder Metastasis of Chromophobe Renal Cell Carcinoma: Report of a Case
  新田 聡; 末富 崇弘; 古城 公佑; 志賀 正宣; 及川 祥生; 黒部 匡広; 市岡 大士; 吉野 喬之; 高岡...
  Acta urologica Japonica, 2016-02
• [Metachronous Bilateral Testicular Tumors with Frequently Recurrent Hydrocele : A Case Report]
  Nitta Satoshi; Sakka Shotaro; Endo Tsuyoshi; Komine Mana...
  Hinyokika kiyo. Acta urologica Japonica, 2017-03
• Impact of hemoglobin levels on hemoglobin-adjusted carbon monoxide diffusion capacity after chemotherapy for testicular cancer
  Nitta Satoshi; Kawai Koji; Nagumo Yoshiyuki; Kandori Shu...
  Japanese journal of clinical oncology, 2019-07
• Fever, Hepatic Dysfunction and Interstitial Pneumonia Caused by Intravesical Bacillus Calmette-Guerin (BCG) Instillation after Urethral Bougie : A Case Report
  Nitta Satoshi; Sakka Shotaro; Endo Tsuyoshi; Komine Mana...
  Acta urologica Japonica, 2017-10
• Machine learning methods can more efficiently predict prostate cancer compared with prostate-specific antigen density and prostate-specific antigen velocity
  Nitta Satoshi; Tsutsumi Masakazu; Sakka Shotaro; Endo Ts...
  PROSTATE INTERNATIONAL, 2019-09
• Predictors of venous thromboembolism development before and during chemotherapy for advanced germ cell tumor
  Nitta Satoshi; Kawai Koji; Kimura Tomokazu; Kawahara ...
  Japanese journal of clinical oncology/50(3)/pp.338-343, 2020-03
  
  PubMed
• Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan
  Ikeda Atsushi; Kojima Takahiro; Kawai Koji; Hinotsu Shir...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/25(6)/pp.1163-1169, 2020-03
  
  PubMed
• Co-Morbidity Among Childhood Cancer Survivors at "The Comprehensive Medical Checkup for CCS at University of Tsukuba Hospital"
  Fukushima Hiroko; Suzuki Ryoko; Yamaki Yuni; Hosaka Sho; ...
  PEDIATRIC BLOOD & CANCER/66(5:SI)/pp.S90-S90, 2019-12
• 膀胱癌に対するAtezolizumab併用放射線療法：第Ⅱ相医師主導多施設共同治験プロトコル
  関野 雄太; 石川 仁; 木村友和; 東治人; 吉田謙; 影山幸雄; 齋藤吉弘; 都築豊徳; 西山博之
  日本放射線腫瘍学会第32回学術大会報文集/pp.276-267, 2019-11
• The impact of histologic variants of urothelial carcinoma on clinical outcomes following trimodal bladder-preserving therapy.
  Nagumo Yoshiyuki; Kandori Shuya; Kimura Tomokazu; Kawahar...
  JOURNAL OF CLINICAL ONCOLOGY/37(7::S), 2019-03
• Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.
  Kamat Ashish M.; Shore Neal D.; Hahn Noah M.; Alanee Sha...
  JOURNAL OF CLINICAL ONCOLOGY/37(7::S), 2019-03
• The role of adjuvant chemotherapy for pT2-4 upper urinary tract urothelial cancer: Exploratory analysis of large multi-institutional study (JCOG1110A).
  Inokuchi Junichi; Kuroiwa Kentaro; Nishiyama Hiroyuki; Ko...
  JOURNAL OF CLINICAL ONCOLOGY/37(7::S), 2019-03
• A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
  Hahn Noah M.; Chang Sam S.; Meng Maxwell; Shore Neal D.; ...
  JOURNAL OF CLINICAL ONCOLOGY/37(7::S), 2019-03
• A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
  De Santis Maria; Abdrashitov Ramil; Hegele Axel; Kolb Ma...
  JOURNAL OF CLINICAL ONCOLOGY/37(7::S), 2019-03
• Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
  Balar Arjun Vasant; Kulkarni Girish S.; Uchio Edward M.; ...
  JOURNAL OF CLINICAL ONCOLOGY/37(7::S), 2019-03
• Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
  Van der Heijden M.; Powles T.; Petrylak D.; de Wit R.; Ch...
  ANNALS OF ONCOLOGY/30(5), 2019-10
• Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
  de Wit R.; Kulkarni G. S.; Uchio E.; Boormans J. L.; Roum...
  ANNALS OF ONCOLOGY/30(5), 2019-10
• Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey
  Choo Seol Ho; Nishiyama Hiroyuki; Kitamura Hiroshi; Ch...
  International journal of urology : official journal of the Japanese Urological Association/26(12)/pp.1121-1127, 2019-12
  
  PubMed
• more...